Sign In
Buy CNS
$70.20
-1.00 (-1.40%)
At Close: Jun 03, 2026
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
08:00am, Wednesday, 26'th Jun 2024
HOUSTON, TX / ACCESSWIRE / June 26, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary
Cohen & Steers Closed-End Funds Declare Distributions for July, August, and September 2024
06:12pm, Monday, 24'th Jun 2024
NEW YORK , June 24, 2024 /PRNewswire/ -- The Boards of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for July, August, and September 2024, as summarized in
Cohen & Steers Announces Succession of Chief Financial Officer
04:16pm, Monday, 24'th Jun 2024
Raja Dakkuri joins Cohen & Steers to succeed Matthew Stadler NEW YORK , June 24, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that Raja Dakkuri has joined Cohen & Steers as Ex
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
Corero Network Security Enhances SmartWall ONE Service Portal
07:00am, Thursday, 20'th Jun 2024
MARLBOROUGH, Mass. and EDINBURGH, United Kingdom , June 20, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, tod
- FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held June 20 th at 8:00 am EDT - WARREN, N.J. , June 20, 2024 /PRNewswire/ -- PTC Therapeutics, I
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
03:11pm, Friday, 14'th Jun 2024
HOUSTON, TX / ACCESSWIRE / June 14, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary
A2 Hosting Expands Commitment to DDoS Protection with Corero Network Security
07:00am, Thursday, 13'th Jun 2024
MARLBOROUGH, Mass. , June 13, 2024 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, announced the renewal and
Corero Network Security Wins 2024 Visionary Spotlight Award for Cybersecurity (Business Technology)
07:00am, Wednesday, 12'th Jun 2024
MARLBOROUGH, Mass. , June 12, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, is pleased to announce that it h
Cohen & Steers (CNS) May AUM Balance Rises on Upbeat Markets
09:40am, Tuesday, 11'th Jun 2024
Cohen & Steers (CNS) reports an improvement in the May 2024 AUM balance on solid market performance.
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows For May 2024
04:20pm, Monday, 10'th Jun 2024
NEW YORK , June 10, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $80.5 billion as of May 31, 2024, an increase of $3.3 billion from asse
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
11:46pm, Wednesday, 05'th Jun 2024
ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue. Nuplazid, indicated for Parkin
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice
Cohen & Steers Appoints Daniel Noonan as Head of Wealth Management Consulting Group
09:00am, Wednesday, 05'th Jun 2024
NEW YORK , June 5, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) has named Daniel Noonan as Executive Vice President and Head of the Wealth Management Consulting Group. In this role, Mr.
The 4 Factor Dividend Growth Strategy - Cooling Off In The Second Half Of Fiscal Year 2
08:25am, Tuesday, 04'th Jun 2024
The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF with a few minor twists. The portfolio gained 1.28% in May, trailing
